## Abstract We show that flavonoids positively regulate type‐II estrogen‐binding site (type‐ll EBS) levels both in MCF‐7 (ER‐positive) and in MDA‐MB231 (ER‐negative) breast‐cancer cells. Type‐ll EBS were measured by a whole‐cell assay at 4°C for 2.5 hr using [^3^H]‐estradiol as tracer. In both cell
Peroxisome proliferator–activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231
✍ Scribed by Kate M. Suchanek; Fiona J. May; Jodie A. Robinson; Won Jae Lee; Nicola A. Holman; Gregory R. Monteith; Sarah J. Roberts-Thomson
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 118 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.10061
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Peroxisome proliferator–activated receptor (PPAR) α is a ligand‐activated transcription factor that has been linked with rodent hepatocarcinogenesis. It has been suggested that PPARα mRNA expression levels are an important determinant of rodent hepatic tumorigenicity. Previous work in rat mammary gland epithelial cells showed significantly increased PPARα mRNA expression in carcinomas, suggesting the possible role of this isoform in rodent mammary gland carcinogenesis. In this study we sought to determine whether PPARα is expressed and dynamically regulated in human breast cancer MCF‐7 and MDA‐MB‐231 cells. Having established the presence of PPARα in both cell types, we then examined the consequence of PPARα activation, by its ligands Wy‐14,643 and clofibrate, on proliferation. With real‐time reverse transcriptase–polymerase chain reaction, we showed that PPARα mRNA was dynamically regulated in MDA‐MB‐231 cells and that PPARα activation significantly increased proliferation of the cell line. In contrast, PPARα expression in MCF‐7 cells did not change with proliferation during culture and was present at significantly lower levels than in MDA‐MB‐231 cells. However, PPARα ligand activation still significantly increased the proliferation of MCF‐7 cells. The promotion of proliferation in breast cancer cell lines following PPARα activation was in stark contrast to the effects of PPARγ‐activating ligands that decrease proliferation in human breast cancer cells. Our results established the presence of PPARα in human breast cancer cell lines and showed for the first time that activation of PPARα in human breast cancer cells promoted proliferation. Hence, this pathway may be significant in mammary gland tumorigenesis. © 2002 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Lactogenic hormones which bind to the PRLR are likely to be growth-stimulatory in human breast-cancer cells. Oestrogen and progesterone control cellular expression of the PRLR however, elevated androgen levels in some breast-cancer patients raised the possibility that androgens may also influence br
## Abstract Some kinds of breast cancer cell lines, similar to several types of solid tumors, express epidermal growth factor receptor (EGFR). However, gefitinib, an EGFR tyrosine kinase inhibitor, is not effective for all these cell lines. Similarly, taxane is effective for many of the cell lines,
Oxytocin (OT) inhibits the proliferation of breast-cancer cells in vitro via a specific G-coupled receptor. To elucidate the intracellular mechanism involved in this biological effect, different G-coupled receptor mediators have been investigated in untreated and OT-treated MDA-MB231 breastcarcinoma
MDA-MB-231 (MDA-231) human breast cancer cells have a high proliferation rate, lack the estrogen receptor, express the intermediate filament vimentin, the hyaluronan receptor CD44, and are able to form tumors in nude mice. The MDA-231 cell line has been used in our laboratory to examine the role of